

An abstract graphic in the top left corner consisting of a network of glowing blue nodes connected by thin lines, resembling a molecular or digital structure.

inhalerRx

The Future of Inhaled Medicine

Authorised by the Board of Directors

Why Change From Lifespot Health Ltd?

InhaleRx Ltd is the natural evolution of Lifespot Health Ltd, in 2020 the Board and Management of Lifespot Health recognised that the strategic direction and future focus of Lifespot Health Ltd had changed significantly to the point that the name no longer reflected the companies goals, aspirations and strategic direction.

Lifespot Health Ltd had originally been named to reflect its early clinical focus on screening technology for Skin Cancer, however as Lifespot Health Ltd evolved with the fast changing medical device market, Lifespot Health Ltd's focus had refocused onto inhaled medicine delivery systems, and hence InhaleRx Ltd was born.

Why InhaleRx?

The new name is a combination of "Inhale", and "Rx" the common shorthand for prescription, which better reflects the companies focus on medical inhalation devices for the delivery of prescribed medicines.

InhaleRx Ltd adding Shareholder Value

A clear split for Lifespot Health Ltd's corporate brand will provide investors with a clear vision of the future strategic focus




Brand Image

- Telehealth & Digital
- Disease Monitoring
 - Skin Cancer
 - Blood Glucose
 - Cannabis Vapes (Seng Vital)
 - COVID & Temperature monitoring (FeverTel)
- Bluetooth Devices
- Secure Cloud based data sharing between patients & Doctors (BodyTel)
- Image scattered between diseases, devices and delivery systems, no clear image.

Brand Image

- Inhaled Prescription Medical Devices
- Clinical Trials
- Simple for Investors and customers to understand what we do and the value we add.
- Clean Focused Image

InhaleRx Ltd Branding supported by promotional activities



Our Vision

To provide the most innovative inhaled therapies in the world.

Our Mission

To deliver the unique benefits of inhaled medication systems to patients in an affordable and high-quality format, supported by strong clinical evidence. We will achieve this by partnering with innovators and educators in their technical and therapeutic fields, to provide inhalation breakthrough therapies that deliver added value for patients, doctors, business partners, governments and stakeholders alike.




Our Values



Innovation

We accept that there is always a better way, the road to success is in finding it.




Transparency

We communicate clear goals, objectives and outcomes to all stakeholders.



Reliability

We do what we say we will do.



Integrity

Integrity leads our decision making.



The InhaleRx Ltd Team



Matthew Golden
Chief Executive Officer

- Commercial healthcare Professional with 20 years' experience in the pharmaceutical industry
- Experienced leader in both Australian and international pharmaceutical markets.
- Strong experience launching mega brands such as Caduet® and Eliquis® and developing turnaround growth strategies for products such as Accupril® and Pentrox® (the 'Green Whistle').



Dr. Sud Agarwal
Medical Science Consultant

- Dr Agarwal is an anaesthetist and the Co-Founder of Cannvalate.
- Chief Medical Officer at Incannex Healthcare Ltd.
- Sud is considered a global cannabis key opinion leader advocating for clinically-validated cannabinoid treatment..



Sean Williams
Non-Executive Chairman

- Senior executive who has had a successful career across the supply chain, health, pharmaceutical and investment sectors.
- Experience as CEO of investment company with Assets Under Management of \$475m+
- Ex- General Manager Finance and General Manager; Hospital Pharmacy & Dental Distribution Services for Symbion Pharmacy



Andrew Saich
Non-Executive Director

- Andrew is a UK trained physician with a degree in physiology and a degree in medicine from the University of London.
- Andrew has vast experience within the pharmaceutical and medical cannabis industries as a Senior Executive leading the medical team at GW Pharmaceuticals, Chief Medical Officer at Senzer Pharmaceuticals & European Medical Director for Intercept Pharmaceuticals



Darryl Davies
Non-Executive Director

- Chief Operating Officer & Co-founder of Cannvalate
- Darryl is a hands-on executive with a broad-ranging cannabis experience including operations, education & sales.
- Darryl holds a Bachelor of Science Degree and a Diploma of Management

**Nova Taylor &
Elizabeth Spooner**
Company co-Secretaries

The InhaleRx Strategic Imperatives remain focused

Short Term – Market Testing

- Launch of Australia's 1st Medical Cannabis Sealed Pod Inhalation System
 - Sealed Pod for supply chain security
 - Breath actuated for ease of use
 - CBD Pods developed and sold by EC Pharma Pty Ltd
 - Distribution primarily through Cannvalate doctor network
- Early Patient feedback has been very positive



The InhaleRx Strategic Imperatives remain focused

Medium Term – New Product Development

- Focused on Medical Quality Devices that meet Patient, Physician and Clinical Trial Requirements
- Ongoing collaboration with Medical Device Engineering Consultants
- Discovery of new Inhalation Technologies
- Development & Discovery of Manufacturing Systems
 - GMP Validated systems
 - ISO 13485 standards
 - CMC, QA and Tracking systems
- Discovery, review and development of inhalation devices to meet regulatory requirements of FDA, TGA, European and other key market regulatory authorities.



The InhaleRx Strategic Imperatives remain focused

Long term – Product Validation & Registration

- InhaleRx Ltd.'s long term focus is to develop 1st to market, medically registered and integrated inhaled medical cannabis delivery systems.
- Regulatory Partnership with Camargo to develop comprehensive registration package utilising FDA's 505(b)(2) pathway will result in reduced time to market and costs.
- Working closely with EC Pharma Pty Ltd who are developing proprietary formulations to work specifically with InhaleRx's devices.
- Develop Regulatory Package for Pre-IND meeting.
- Work on Orphan Disease Designation, identification of available USDMF's and data packages has already commenced with the aim of conducting Pre-IND meetings with FDA.



Commercial Activities Update

Market Expansion of Medihale

- Negotiating with multiple companies wanting to launch white label Pods for use with the Medihale Inhaler Device
- Conducting Medical Cannabis Clinic Product Training sessions
- Development of Medihale Medical Education materials to support prescribing of Medihale Pods and Devices
- Investigation into new therapeutic areas for InhaleRx Devices to meet the needs of patients

New Product Development

- Investigating several options for new clinical devices including inhaled heated vaporisers and other suitable inhalation devices that meet regulatory and clinical requirements.
- Development of Medihale Medical Education materials to support prescribing of Medihale Pods and Devices



Thankyou

InhaleRx Ltd (ASX:IRX) - Pending Share Holder approval
www.InhaleRx.com.au

 Suite 103, 2 Queen Street, Melbourne

 (03) 8395 5446

 info@lifespot-health.com

Authorised by the Board of Directors

 info@InhaleRx.com.au